ArticleOncoTargets and therapy2024

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.

Ruoxin Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.